Sirtex: SIRFLOX Study Abstract Released by ASCO
Sirtex Medical Limited’s (ASX: SRX) SIRFLOX Study of 530 patients revealed median progression-free survival (PFS) in the liver of 20.5 months, an improvement of 7.9 months over the current standard chemotherapy plus Avastin.
The p-ratio of 0.2 per cent indicates extremely high statistical significance while the hazard ratio of 0.69 indicates patients on SIR-Spheres had a 31 per cent lower risk of tumours in the liver progressing whilst on the study.
Interestingly, the complete response rate in the liver – or complete disappearance of tumours in the liver – was 6 per cent with SIR-Spheres, more than triple the standard chemotherapy plus Avastin alternative.
The presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 30 May 2015 is expected to reveal “important new information…that facilitates a greater understanding of the implications and impact of the SIRFLOX study for SIR-Spheres Y-90 resin microspheres in first line mCRC, and how this may apply to clinical practice”.
Overall survival (OS) requires the FOXFIRE and FOXFIRE Global study results to achieve statistical significance in over 1,000 patients, when released in approximately two years time.
In the meantime global dose sales for the ten months to April 2015 were up 22 per cent year on year, and this could exceed 10,500 in the 2015 financial year.
The Montgomery [Private] Fund and The Montgomery Fund are shareholders in Sirtex Medical Limited.
To learn more about our funds, please click here, or contact me, David Buckland, on 02 8046 5000 or at dbuckland@montinvest.com.
Chief Executive Officer of Montgomery Investment Management, David Buckland has over 30 years of industry experience. David is a deeply knowledgeable and highly experienced financial services executive. Prior to joining Montgomery in 2012, David was CEO and Executive Director of Hunter Hall for 11 years, as well as a Director at JP Morgan in Sydney and London for eight years.
This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.
jerome mellor
:
Hi David,
Many chemo studies show an improvement in survival of 2-3months in those otherwise terminally ill with cancer and often this time is swallowed up in illness due to the side-effects of Chemo, hence the benefits become debatable.
Under these dire circumstances, an improvement of nearly 8 months in this situation is quite fantastic!
Roger Montgomery
:
Thanks Jerome. We thought so too.
Greg McLennan
:
Hi David,
Technically the p-value was 0.002 but we get what you mean. The statement from Sirtex
“important new information…that facilitates a greater understanding of the implications and impact of the SIRFLOX study for SIR-Spheres Y-90 resin microspheres in first line mCRC, and how this may apply to clinical practice”.
gives an indication of what the company expects from the results in terms of acceptance of the intervention. The increase in PFS in the liver was significant in both the research sense and common usage sense of the word.
John Boardman
:
Hi Roger,
Thanks for the update on SRX.
Are you also still holding Resmed? What are your views on RMD? The announcement yesterday wasn’t well received by the market.